Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABVC vs CONX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVC Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–1 Matrix Metrics)

ABVC Overall Winner 6-Pillar Tally: ABVC 3 – 1 CONX (2 Tie) Matrix Metrics: ABVC 7 – 1 CONX

As of Nov 16, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABVC carries a Unified Composite Score of 39.0/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin), whereas CONX carries 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While CONX currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. ABVC 39.0/100 SELL), ABVC captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY).
  • Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.7); meanwhile CONX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABVC vs CONX
ABVC NASDAQ Head-to-Head Winner
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+3.3% 1D
Market Cap $24.5M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.34β · 56% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 32.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.7 · SMA20: $1.00 · SMA50: $1.02
CONX US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.88β · 135% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 25.0 Fund 54.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.9%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $4.23 · SMA50: $5.78

6-Pillar Scorecard Institutional Category Breakdown (ABVC 3 – 1 CONX)

Columns: Metric · ABVC · CONX
1. Valuation Multiples ABVC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 30.8x N/M
2. Growth & Scale ABVC
Revenue Growth (YoY) +104.5% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $797,916 N/A
Market Cap $24.5M N/A
3. Profitability & Quality ABVC
Gross Margin 100.0% N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -52.7% N/A
4. Balance Sheet & Cash Flow CONX
Cash Generation (TTM) -$5.8M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.49 Book/Sh · -52.7% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABVC (7) vs CONX (1)
Institutional Metric ABVC CONX Criterion Row Edge
Market Capitalization
Scale
$24.5M N/A Larger Scale ABVC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+104.5% N/A Higher Growth ABVC
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin ABVC
Net Profit Margin
Profitability
0.0% N/A Higher Margin ABVC
Return on Equity (ROE)
Capital Efficiency
-52.7% N/A Higher ROE ABVC
52-Week Range Position
Momentum
10% ($1–$3) 0% ($3–$28) Stronger Trend ABVC
Beta / 30D Volatility
Risk Regime
1.34β · 56% Vol 4.88β · 135% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
39.0 / 100 (SELL) 42.0 / 100 (HOLD) Higher Composite CONX
Trailing 12M Revenue (USD)
Operating Scale
$797,916 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 30.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.8M EBITDA ($0.49 Book/Sh · -52.7% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVC +57.07 pp
ABVC: +2.41% · CONX: -54.66%
3M Horizon ABVC +52.87 pp
ABVC: +8.53% · CONX: -44.34%
6M Horizon ABVC +59.11 pp
ABVC: -12.15% · CONX: -71.26%
1Y Horizon ABVC +23.53 pp
ABVC: -65.44% · CONX: -88.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs CONX. Trailing 12-month operating profitability (ABVC 0.0% vs CONX N/A) and valuation multiples (ABVC N/M vs CONX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M
CONX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CONX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CONX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $24.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CONX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABVC vs CONX Key Questions & Quantitative Answers

As of Nov 16, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over CONX (CONX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABVC carries a Unified Composite Score of 39.0/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin), whereas CONX carries 42.0/100 (HOLD) at $2.66 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CONX currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. ABVC 39.0/100 SELL), ABVC captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+104.5% vs. N/A YoY). Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.7); meanwhile CONX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVC leads the Growth & Scale pillar: ABVC posts +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin), compared with CONX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABVC generates $797,916 in USD-normalized revenue versus N/A for CONX. In operating R&D and SG&A reinvestment, ABVC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CONX.

ABVC screens cheaper on headline valuation multiples. ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.8x EV/Revenue (unreported EBITDA margin), whereas CONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABVC (-52.7% ROE) versus CONX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 56% Vol realized risk). By comparison, CONX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.88β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.